Filing Flows › Haemonetics (HAE) › Q4 FY25
Haemonetics (HAE) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed May 21, 2025
Haemonetics (HAE) reported revenue of $331M for the fourth quarter fiscal 2025 (Q4 FY25), -4% from a year earlier and -5% from the quarter before. Operating margin was 21.6%, net earnings $58.0M (17.5% of revenue).
Haemonetics, Q4 FY25: revenue $331M (-4% year over year), operating margin 21.6%, net earnings $58.0M, operating cash flow $117M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $331M | -5% | -4% |
| Gross profit | $193M | -0.3% | +10% |
| Operating profit | $71.3M | +21% | +138% |
| Net earnings | $58.0M | +55% | +185% |
| Operating cash flow | $117M | +166% | +82% |
| Free cash flow | $101M | +187% | +76% |
What changed
Revenue was $330.6M in Q4 FY25, down 4% year over year and down 5% from the previous quarter.
Gross margin was 58.4%, up 7.2 points from a year earlier. Operating profit was $71.3M, a 21.6% margin (up 12.9 points year over year). Operating expenses fell 17% while revenue fell 4%. Net earnings were $58.0M, up 185% year over year. The effective tax rate was 18.0%.
Operating cash flow was $116.6M (up 82% year over year), 201% of net earnings. Non-cash charges added back $28.2M of depreciation and amortization and $6.9M of share-based compensation. Working capital and other items added $23.4M. Capital expenditures of $15.6M left free cash flow of $100.9M.
Questions
What was Haemonetics' revenue in the fourth quarter fiscal 2025?
Haemonetics (HAE) reported revenue of $331M for the fourth quarter fiscal 2025 (Q4 FY25), -4% from a year earlier and -5% from the quarter before.
Was Haemonetics profitable in the fourth quarter fiscal 2025?
Operating profit was $71.3M (21.6% of revenue) and net earnings $58.0M.
Source: Haemonetics 10-K on SEC EDGAR.